<DOC>
	<DOCNO>NCT01595438</DOCNO>
	<brief_summary>The purpose study evaluate effect Ceftazidime Avibactam compare Doripenem treat hospitalized patient complicate urinary tract infection , include acute pyelonephritis</brief_summary>
	<brief_title>Ceftazidime-Avibactam Compared With Doripenem Followed Oral Therapy Hospitalized Adults With Complicated UTIs ( Urinary Tract Infections )</brief_title>
	<detailed_description>A Phase III , Randomized , Multicenter , Double-Blind , Double Dummy , Parallel Group , Comparative Study Determine Efficacy , Safety , Tolerability Ceftazidime Avibactam ( CAZ-AVI , formerly CAZ104 ) Versus Doripenem Followed Appropriate Oral Therapy Treatment Complicated Urinary Tract Infections , Including Acute Pyelonephritis , With Gram Negative Pathogen Hospitalized Adults</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Urinary Tract Infections</mesh_term>
	<mesh_term>Pyelonephritis</mesh_term>
	<mesh_term>Avibactam</mesh_term>
	<mesh_term>Avibactam , ceftazidime drug combination</mesh_term>
	<mesh_term>Sulfamethoxazole</mesh_term>
	<mesh_term>Trimethoprim</mesh_term>
	<mesh_term>Ciprofloxacin</mesh_term>
	<mesh_term>Ceftazidime</mesh_term>
	<mesh_term>Trimethoprim , Sulfamethoxazole Drug Combination</mesh_term>
	<criteria>18 90 year age inclusive Female patient participate surgically sterile complete menopause female capable child agree attempt pregnancy receive IV study therapy period 7 day Has pyuria &gt; /= 10 WBCs ( white blood cell ) positive urine culture within 48 hour enrollment contain &gt; /=10 fifth CFU ( colony form unit ) /ml recognize uropathogen know susceptible IV study therapy ( CAZAVI doripenem ) Demonstrates either acute pyelonephritis complicate low UTI without pyelonephritis . Urine pathogen Grampositive pathogen uropathogen resistant CAZAVI doripenem Patient 's urine culture study entry isolate 2 microorganism regardless colony count patient confirm fungal UTI Patient receive hemodialysis peritoneal dialysis renal transplant Patient immunocompromised Patient consider unlikely survive 6 8week study period rapidly progressive terminal illness include septic shock associate high risk mortality</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Ceftazidime , Avibactam , Doripenem , Ciprofloxacin , sulfamethoxazole/trimethoprim , Anti-Infective Agents , Complicated Urinary Tract Infection , Acute Pyelonephritis</keyword>
</DOC>